Clinical Study
A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen
Table 2
Incidence of neutropenia, febrile neutropenia, and other adverse effects.
| ||||||||||||||||||||||||||||||||||||||||||
The percentage is calculated out of the 394, the total number of patients in the study’s cohort. |